이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Neurocognitive Integrity After Proton Therapy for Brain Tumor (PROTON MIND)

2026년 9월 22일 업데이트: European Institute of Oncology

Prospective Evaluation of Neurocognitive Integrity After Proton Therapy for Brain Tumor

Radiation therapy remains a cornerstone in the management of both benign and malignant intracranial tumors, either as monotherapy or combined with surgery and/or chemotherapy. Despite its therapeutic benefits, it is frequently associated with potential long-term adverse effects, with neurotoxicity posing a major challenge, especially in young patients affected by benign primary tumors.

연구 개요

상태

아직 모집하지 않음

상세 설명

In the brain, late radiotoxicities typically manifest as cognitive dysfunction, leukoencephalopathy, brain atrophy, brain tissue necrosis, cerebrovascular complications, endocrinopathies, and/or secondary malignant neoplasms.

Radiation-induced hippocampal injury, in particular, significantly contributes to cognitive impairment, while broader central nervous system effects arise through multiple mechanisms, including vascular injury, neuronal depletion, chronic inflammation, demyelination, and tissue necrosis.

The severity of cognitive dysfunction depends on multiple factors, including the location and the volume of the tumor, the total radiation dose administered, the fractionation regimen, and the individual susceptibility of the patient, as well as comorbidities (e.g., diabetes, etc.) and concomitant drugs.

The distinct physical characteristics of proton therapy, such as a reduced entrance dose, an eliminated exit dose, and a Bragg peak, provide clear dosimetric advantages over conventional photon treatments. Pencil-beam scanning further improves on earlier passive scattering approaches by delivering modulated proton beamlets for superior target conformality and reduced neutron scatter, thereby limiting low- and intermediate- dose exposure to cranial organs at risk (OARs) while preserving adequate dose coverage within the target volume.

From a radiobiological standpoint, these properties suggest that proton therapy may present a more favorable risk-benefit balance compared to photon-based modalities, particularly for long-term clinical outcomes. It achieves a drastic reduction in the integral dose, offering substantial benefit in decreasing radiation-induced second malignancies, making it mandatory for children when available.

Proton therapy is well established for treating pediatric tumors, CNS tumors such as low-grade gliomas (LGG) and meningiomas, especially if near the optic pathway or brainstem, and all the benign tumors in young patients. In these cases, the primary goal extends beyond curing the disease to preserving neurological and cognitive functions.

연구 유형

관찰

등록 (추정된)

60

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Italy
      • Milan, Italy, 이탈리아, 20141
        • European Institute of Oncology, Milan

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Patients affected by primary central nervous system tumors and eligible for protontherapy as adjuvant or radical treatment

설명

Inclusion Criteria:

  • Primary tumors of Brain Tumor (CNS), benign and malignant
  • Age ≥ 18 years
  • Patients able to speak and read the local language(s) fluently
  • Acceptance and signature of informed consent
  • Radiological diagnosis, biopsy, or previous surgery
  • Concomitant medical therapy is allowed

Exclusion Criteria:

  • Previous brain radiotherapy (any form)
  • High-grade gliomas
  • Patients with concomitant neurological or psychiatric disorders.
  • Pregnancy

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
The presence of cognitive impairment
기간: From the end of Protontherapy through study completion, an average of 1 year.

The primary endpoint will be the presence of cognitive impairment during the first 5 years after enrollment, as measured by a comprehensive neuropsychological assessment.

From the end of Protontherapy through study completion, an average of 1 year.

2차 결과 측정

결과 측정
측정값 설명
기간
Perceived cognitive impairment
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Functional Assessment of Cancer Therapy-cognition (FACT-cog) 37 items will be completed (score 1-4)

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Depressive symptoms
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

At Beck Depression Inventory-II (BDI-II) 21 items will be completed (score 0-3)

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Anxiety
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For State-Trait Anxiety Inventory (STAI) 40 items will be completed (score 1-4)

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Quality of Life data (QoL) - EORTC QLQ C30 questionnaires.
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For EORTC QLQ C30, 30 items will be completed (score 1-4).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Sleep quality
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Pittsburgh Sleep Quality Index (PSQI) 24 items will be completed (score 0-3)

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Cognitive Reserve
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Cognitive Reserve Index questionnaire (CRIq) 20 items will be completed (core 0-1)

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Global functioning
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Montreal Cognitive Assessment (MoCA) 30 items will be completed (score 1-5).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Learning and Verbal Memory
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Rey Auditory Verbal Learning Test (RAVLT) 15 items will be completed (score 0-4).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Working memory
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Corsi Span backward/forward 18 items will be completed (score 0-4).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Visual memory
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Rey-Osterrieth complex figure -recall 18 items will be completed (score 0-2).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Visuospatial abilities
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Rey-Osterrieth complex figure -copy 18 items will be completed (score 0-2).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Executive function
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Frontal Assessment Battery (FAB) 30 items will be completed (score 0-3).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Attention
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Symbol digit modalities test (SDMT) 110 items will be completed (score 0-1)

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 9월 1일

기본 완료 (추정된)

2031년 7월 1일

연구 완료 (추정된)

2036년 7월 1일

연구 등록 날짜

최초 제출

2026년 9월 14일

QC 기준을 충족하는 최초 제출

2026년 9월 22일

처음 게시됨 (실제)

2026년 9월 23일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 23일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 22일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • UID 5445
  • L2-684 (기타 식별자: Comitato Etico Lombardia 2)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다